8月12日，诺和诺德盘中下跌3.05%，报46.05美元/股，成交额8214.8万美元。
消息面上，投行贝伦贝格将诺和诺德评级从"买入"下调至"持有"，同时将目标价从50美元下调至47美元。据FactSet统计，该股当前分析师平均评级为"增持"，平均目标价49.12美元。市场对诺和诺德GLP-1产品增长放缓及与礼来竞争压力加大的担忧持续发酵，叠加投行下调评级与目标价，进一步压制市场情绪。
诺和诺德所在的制药行业中，礼来跌0.66%，默沙东涨0.74%，强生跌0.76%，辉瑞跌0.92%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.